Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentian Violet for Hidradenitis Suppurativa
NCT04388163Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gentian violet in hidradenitis suppurativa (HS), sponsored by Wake Forest University Health Sciences. Primary endpoints: Skin's Redness, Skin's Drainage and 1 more. Planned start Aug 2025; status: withdrawn.
02
Drugs
gentian violet
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04388163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388163.